Indu Javeri, Author at CuriRx, Inc.

CuriRx Launches the Advanced Bioprocessing and Analytical Center to Support Biotherapeutic Drug Developers

WILMINGTON, Mass., Jan. 26, 2022 /PRNewswire/ — CuriRx, Inc., a leading contract research, development and manufacturing organization (CRDMO), announced today the launch of the Advanced Bioprocessing […]

Sign up for CuriRx’s Complimentary Lunch & Learn on November 9 at MassBio!

Join CuriRx for a complimentary lunch & learn about our CuriLytics® platform! CuriLytics®: De-risking CMC characterization by using high-resolution mass spectrometry Date: Tuesday, November 9th, 2021 […]

CuriRx Launches CuriLytics® Platform to Provide CMC Analytical Services to Support Complex Biotherapeutic Development Using High Resolution Mass Spectrometry

WILMINGTON, Mass., Sept. 21, 2021 /PRNewswire/ CuriRx, Inc., a leading contract research, development and manufacturing organization(CRDMO), announced today the launch of their new CuriLytics® platform with High-Resolution […]

Characterization of Co-Formulated High-Concentration Broadly Neutralizing Anti-HIV-1 Monoclonal Antibodies for Subcutaneous Administration

Introduction Antibodies 2020, 9(3), 36; https://doi.org/10.3390/antib9030036 (registering DOI) Received: 26 June 2020 / Revised: 21 July 2020 / Accepted: 23 July 2020 / Published: 29 July 2020 (This article […]